Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients
NCT07052734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2843
Last updated 2025-07-06
Summary
Update and validate the performance of the 21-gene score in prognostic stratification for early-stage HR-positive, HER2-negative breast cancer in China.
Conditions
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2025-06-18
- Completion
- 2025-06-18
Countries
- China
Study Locations
More Related Trials
-
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
NCT05510037 ·Status: COMPLETED
-
The Treatment Situation of Chinese County Population With Breast Cancer
NCT05544123 ·Status: UNKNOWN
-
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039 ·Status: RECRUITING
-
Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery
NCT04145973 ·Status: UNKNOWN
-
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients
NCT05901025 ·Status: NOT_YET_RECRUITING
-
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
NCT05079074 ·Status: COMPLETED
-
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
NCT01198301 ·Status: COMPLETED
-
Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
NCT07093775 ·Status: NOT_YET_RECRUITING
-
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
NCT06102018 ·Status: RECRUITING
-
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
NCT06718010 ·Status: RECRUITING
-
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
NCT04265937 ·Status: RECRUITING
-
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
NCT07056205 ·Status: ENROLLING_BY_INVITATION
-
Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
NCT07154563 ·Status: RECRUITING
-
The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer
NCT04683757 ·Status: UNKNOWN
-
A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer
NCT04970264 ·Status: UNKNOWN
-
MRD in High-risk EBC
NCT06566729 ·Status: ACTIVE_NOT_RECRUITING
-
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
NCT02656589 ·Status: UNKNOWN
-
RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer
NCT04972448 ·Status: NOT_YET_RECRUITING
-
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients
NCT05754047 ·Status: COMPLETED
-
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients
NCT04145947 ·Status: UNKNOWN
-
Characteristics and Treatment Trends of Young Breast Cancer in China
NCT05068115 ·Status: UNKNOWN
-
Molecular Signature for Breast Cancer
NCT05724407 ·Status: UNKNOWN
-
Familial Breast Cancer in China
NCT06833216 ·Status: NOT_YET_RECRUITING
-
Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer
NCT05767931 ·Status: UNKNOWN
-
Evaluation of Prognostic Monitoring for Young Breast Cancer Patients
NCT04145986 ·Status: UNKNOWN